ArticleAmerican journal of public health2005
Racializing drug design: implications of pharmacogenomics for health disparities.
Article in American journal of public health, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience.Genetics in medicine : official journal of the American College of Medical Genetics · 2008Trial
- Underrepresented populations in genomic research: a qualitative study of researchers' perspectives.BMC medical genomics · 2025Article
- Race, Ethnicity, and Pharmacogenomic Variation in the United States and the United Kingdom.Pharmaceutics · 2023Article
- A scoping review of guidelines for the use of race, ethnicity, and ancestry reveals widespread consensus but also points of ongoing disagreement.American journal of human genetics · 2022Article
- Use of Race in Kidney Research and Medicine: Concepts, Principles, and Practice.Clinical journal of the American Society of Nephrology : CJASN · 2022Article
- Health equality, race and pharmacogenomics.British journal of clinical pharmacology · 2022Review
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Can Drug Repositioning Work as a Systematical Business Model?ACS medicinal chemistry letters · 2020Article
- Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.Pharmacogenomics and personalized medicine · 2019Article
- Challenges and Considerations Related to Studying Dementia in Blacks/African Americans.Journal of Alzheimer's disease : JAD · 2017Article
- Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?The pharmacogenomics journal · 2017Article
- Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.Journal of community genetics · 2016Review
- Pharmacogenomics, human genetic diversity and the incorporation and rejection of color/race in Brazil.BioSocieties · 2015Article
- Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities.Human genomics · 2015Review
- Race and ancestry in the age of inclusion: technique and meaning in post-genomic science.Journal of health and social behavior · 2014Article
- The peopling of the African continent and the diaspora into the new world.Current opinion in genetics & development · 2014Review
- Homogeneity and heterogeneity as situational properties: producing--and moving beyond?--race in post-genomic science.Social studies of science · 2014Article
- Ancestry, Temporality, and Potentiality: Engaging Cancer Genetics in Southern Brazil.Current anthropology · 2013Article
- The use of race, ethnicity and ancestry in human genetic research.The HUGO journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Current practices of using "race" in pharmacogenomics research demands consideration of the ethical and social implications for understandings of group difference and for efforts to eliminate health disparities. This discussion focuses on an "infrastructure of racialization" created by current trajectories of research on genetic differences among racially identified groups, the use of race as a proxy for risk in clinical practice, and increasing interest in new market niches by the pharmaceutical industry. The confluence of these factors has resulted in the conflation of genes, disease, and race. I argue that public investment in pharmacogenomics requires careful consideration of current inequities in health status and social and ethical concerns over reifying race and issues of distributive justice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.